Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT), 'Several Dynamics to Follow But Optics Could Further Improve in 2026'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $35.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "For ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
